National OncoVenture (NOV) announces the support of development of MedPacto’s leading anticancer drug candidate, TEW-7197
Nov 05, 2013PRESS RELEASESHit 4109
Korea National Cancer Center established National OncoVenture (NOV, Director: Dr. In-Chul Kim) for 10-year “Conquering Cancer” program in 2011 and this year NOV selected 2 anticancer drug candidates to support the non-clinical and clinical developments on Oct. 15th. MedPacto’s leading compound, TEW-7197, is one of them. It is a small molecule compound which is originally developed by Ewha Women’s University (Prof. Daekee Kim) supported by the Program for Disease-Based Discovery of Global New Drug Candidates. Its target indications are solid tumors. It is in-licensed from Ewha to MedPacto on Jul. 10th 2013.
|Next||Announcement: An annual general meeting of stockholders|
|Previous||No Previous Post|